Vanderbilt researchers have identified potent monoclonal antibodies against influenza B, particularly FluB-400, offering a new method to prevent and treat the virus. This advancement may also aid in creating a universal flu vaccine. A 3D rendering shows one of the isolated antibodies, FluB-393, binding to the neuraminidase surface glycoprotein of the influenza type B virus to prevent infection.
Seasonal flu vaccines cover influenza B and the more common influenza A but do not stimulate the broadest possible range of immune responses against both viruses. In addition, people whose immune systems have been weakened by age or illness may not respond effectively to the flu shot., can help treat early infection, but they provide limited benefit when the infection is more severe, and they are generally less effective in treating influenza B infections.
Intranasal antibody administration may be more effective and have fewer systemic side effects than more typical routes — intravenous infusion or intramuscular injection — in part because intranasal antibodies may “trap” the virus in the nasal mucus, thereby preventing infection of the underlying epithelial surface, the researchers suggested.
Technology Technology Latest News, Technology Technology Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: SciTechDaily1 - 🏆 84. / 68 Read more »
Source: physorg_com - 🏆 388. / 55 Read more »